Connect with us

Business

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Published

on

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions.

(PRNewsfoto/AIkido Pharma Incorporated)

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company also has granted to the underwriter a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commission.

 

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering is being conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”) on June 18, 2020. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at placements@hcwco.com or by telephone at 646-975-6996. Before investing in this offering, interested parties should read in their entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR

Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

Continue Reading
Advertisement

Business

Partnerships with Key Players Enables GWHP Corp To Source PPE Supplies and COVID-19 Diagnostic Testing Kits

Published

on

By

Looking for premium PPE supplies and COVID-19 tests during the pandemic? Global WholeHealth Partners is proud to announce that because of our longstanding relationship with key players in the industry, we are able to continually source high quality PPE supplies and COVID-19 diagnostic testing kits in wholesale quantities. As the Delta Variant makes its rounds and cases begin to climb, the continued use of PPE and following social distancing guidelines can help slow the spread of the coronavirus.

As we approach fall of 2021, COVID-19 and the contagious Delta Variant is still affecting the world at large. This is even with social distancing measures and mask mandates back in place in many areas. We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

GWHP Corp stands committed to sourcing these in demand products and we are hopeful that as more and more people continue to get vaccinated, that we will get ahead of the virus. For more information, simply visit our medical supply page to view our current inventory and get in touch with our specialists to place your wholesale PPE supplies order or wholesale COVID-19 diagnostic testing kits order. We can be reached at 877-568-4947.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Business

Global WholeHealth Partners Provides Wholesale PPE Supplies and COVID-19 Diagnostic Testing Kits

Published

on

By

Heading into the fall season, COVID-19 cases are on the rise, in part due to the contagious Delta Variant that is making its rounds. Global WholeHealth Partners continues to do its part by supplying in demand PPE supplies and COVID-19 diagnostic testing kits in wholesale quantities to interested parties. With the continued distribution of the major vaccines, we are hopeful that COVID-19 cases will begin to decline. However, until then, the use of PPE supplies and COVID-19 diagnostic testing remains high and we are committed to offering these in demand products at competitive price points.

Even with the vaccines currently in distribution, it is important to remember that we can help slow the spread of COVID-19 by wearing masks in public spaces, social distancing when we can, and quarantining when we are sick. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Contact Global WholeHealth Partners today to place your order for wholesale PPE supplies or wholesale COVID-19 testing kits, or both, depending on your needs. We continue to source and supply these in demand products for our customers across the country. Call 877-568-4947 to start your order now.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Business

GWHP Corp Continues to Supply PPE Supplies and COVID-19 Tests As COVID-19 Cases Surge

Published

on

By

COVID-19 cases are on the climb, especially due to the contagious Delta Variant. Global WholeHealth Partners stands committed to sourcing and supplying in demand COVID-19 diagnostic testing kits and personal protective equipment to help keep you safe. We offer these products in large wholesale quantities and interested parties can visit our medical supply page to view current inventory levels. At this time, we can only do our best to protect ourselves and others by following recommended social distancing guidelines and PPE recommendations.

We are incredibly thankful and hopeful that the Pfizer, Moderna and other major vaccines are making their way to millions of people across the globe. However, continued use of PPE supplies will help slow the spread of the virus so we can end this pandemic. We all can do our part to help slow the spread of COVID-19 by social distancing where we can, staying quarantined when we are sick, and using PPE supplies when leaving the house. Masks wearing is required in most public indoor places such as shopping malls, grocery stores and restaurants and often times negative COVID-19 tests are required for travel.

Get in touch with Global WholeHealth Partners now to place your order for wholesale PPE supplies or wholesale COVID-19 testing kits, or both, depending on your needs. We continue to source and supply these in demand products for our customers across the country. Call 877-568-4947 to start your order now.

About Global WholeHealth Partners OTC (GWHP)
GWHP provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 – 1 ½ hours and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which predict diseases ahead of its industry competitors. Our focus is encompassing, improving, and preserving the quality of life by providing fast, adequate and accurate test results to prompt early treatment and cut cost of accumulated diseases all over the world. By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. MISSION GWHP is committed to building long term shareholder value through the vertical integration of proven, well established business that effectively and efficiently control disease outbreak and significantly reducing health care costs. VISION Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results, empower healthcare professionals to make better diagnostic decisions, and lower healthcare costs.

Continue Reading

Trending